The corona vaccine from Biontech and Pfizer is due to be delivered soon.
Biontech boss Ugur Sahin does not expect a return to normal until winter 2021.
Now Oxford University is stepping up.
The Mainz-based pharmaceutical company
Biontech
and its US partner
Pfizer
have developed a promising
corona vaccine *
.
Biontech
boss
Ugur Sahin *
does not expect a return to
normal
until winter 2021
.
The US pharmaceutical company
Moderna
has presented a
corona vaccine
with an
effectiveness of 94.5 percent
.
(see update from November 16, 1:17 p.m.).
The
University of Oxford
provides the first positive results of its corona vaccine before
(Update of November 19, 13:16)
This news ticker is updated regularly.
Update from November 19, 1:16 p.m
.: The corona vaccines are going in
quick succession
.
Oxford University is
now reporting
a success with its vaccine.
The developed corona vaccine called
ChAdOx1
has "triggered a robust immune response" in
healthy adults between the ages of 56 and 69 and also in those over 70
.
The University of Oxford published the data in the journal The Lancet.
The
University of Oxford
developed the Corona vaccine together with the pharmaceutical company
AstraZeneca
.
The results of the crucial study should be available in December.
"It will definitely be before Christmas," said the head of the university's vaccine group, Prof. Andrew Pollard, the BBC.
The Oxford coronavirus vaccine has been shown to trigger a robust immune response in healthy adults aged 56-69 and 70+.
The data suggest that one of the groups most vulnerable to serious illness and death from COVID-19 could build immunity: https: //t.co/E5uEcHFcrT#OxfordVaccine
- University of Oxford (@UniofOxford) November 19, 2020
Corona vaccine: Federal President addresses a sensitive topic
Update from November 18, 4:15 pm:
"The latest news from the Mainz company Biontech and its American partner Pfizer, as well as that of the US company Moderna, are truly a cause for joy," wrote
Federal President Frank-Walter Steinmeier
in a
guest post
for the
Daily mirror
.
He called for future
corona vaccines
to be
shared
with poorer countries
.
"
Germany
and
Europe
should now give a political signal that they are ready to give up part of these quotas right from the start, for example
to protect
health workers in poorer countries
as quickly as possible," demanded
Steinmeier
.
In addition, he said that Germany
can be proud of
the achievements of the
Biontech
entrepreneurs
Özlem Türeci
,
Ugur Sahin
and their team.
“But it should make us even prouder if we had the
insight
and the
wisdom
to set an
example
for
the world in this situation
” - namely that close
cooperation
in
solidarity
within the EU and internationally “is more than lip service, but literally life-saving ”, wrote the
Federal President
.
Coronavirus: Vaccine from Biontech and Pfizer after the final analysis with a protection of 95 percent
Update from November 18, 2:12 p.m .:
"The data show that our vaccine with a dosage of 30 micrograms can produce a high level of protection against Covid-19 just 28 days after the first dose," said
Biontech
boss
Ugur Sahin
.
The Mainz-based company and its US partner
Pfizer
have
cleared
a decisive hurdle for the possible approval of their
corona vaccine
in the
USA
.
After a final analysis of the crucial study, the vaccine
showed
95 percent protection against Covid-19
.
The two companies announced this in a statement on Wednesday.
They also released
positive data
on the
vaccine's
safety
, which they identified as a milestone for
emergency approval
in the
United States
.
They now want to submit their application to the
US health authority FDA
within a few days
.
The data will also be presented to other regulatory authorities around the world.
BREAKING: We are proud to announce, along with @BioNTech_Group, that the Phase 3 study of our # COVID19 vaccine candidate has met all primary efficacy endpoints.
- Pfizer Inc. (@pfizer) November 18, 2020
Corona vaccine: CureVac wants to build a production network with European partners
Update from November 18, 11.09 a.m.:
The company
CureVac
from Tübingen has announced that it
wants to expand
its
European network in
order to be able to manufacture larger quantities of its vaccine candidate.
The preparations for the start of production and the technology transfer of the
corona vaccine candidate CVnCoV
, as the liquid is called, are underway.
"Based on this strategy, the company intends to significantly increase its existing production capacities for CVnCoV to up to 300 million cans in 2021 and up to 600 million cans in 2022, while at the same time reducing potential risks in the supply chain," the company said on Tuesday with.
In addition, a
large
production facility
funded
by the
European Investment Bank (EIB) is
currently being set up
at
CureVac's
headquarters
in
Tübingen
.
"It is our goal to increase the production capacity within a short period of time in order to ensure a stable supply of our vaccine candidate", explained production director
Florian von der Mülbe
.
The company is currently working with
experienced partners across Europe
to build a solid
production
network.
Geographical proximity is an important factor here in order to facilitate alignment and technology transfer.
CureVac
plans
to initiate
the pivotal
Phase 2b / 3
clinical trial by
the end of 2020.
Corona vaccine: EU Commission agrees contract with CureVac
Update from November 17, 10:40 a.m.:
The
EU Commission
has with the Tübingen company
CureVac
signed a contract to purchase
up to 405 million doses of corona vaccine
.
This was announced by Commission President
Ursula von der Leyen
on Monday afternoon in
Brussels
.
This is the fifth framework agreement with pharmaceutical companies that have a promising vaccine against the
coronavirus
under development.
We continue to work to secure safe & effective vaccines to end the pandemic.
I am glad to announce a new agreement to buy up to 405 million doses of a vaccine produced by the European company @CureVacRNAhttps: //t.co/H1gFQH7FAX
- Ursula von der Leyen (@vonderleyen) November 16, 2020
Corona: Vaccine from the US company Moderna can be stored well
Update from November 16, 3:36 p.m.:
The apparently effective
vaccine from
the US company
Moderna
can be stored for a comparatively long time at normal
refrigerator temperature
.
It is assumed that the agent
mRNA-1273 will
remain stable for 30 days at temperatures of 2 to 8 degrees, according to a statement on Monday.
Previously, a shelf life of seven days at these temperatures was assumed.
Moderna has
now announced that the preparation
mRNA-1273
can be stored
at
minus 20 degrees Celsius for
up to
six months
.
The vaccine could "be stored and transported at temperatures that are usually in existing pharmaceutical freezers and refrigerators," said
Juan Andres
of Moderna, according to the press release.
The
vaccine is
stable for up to 12 hours
at
room temperature
.
Corona vaccine: US expert Fauci enthusiastic about published data
The renowned US immunologist and corona expert
Anthony Fauci
responded
with enthusiasm to the
data published
by
Moderna
.
"These are obviously very exciting results," he said, according to
CNN
.
"It doesn't get any better - 94.5 percent are really excellent," says
Fauci
.
According to him, the
first vaccinations
in the
US could start
in
December
for
high-risk groups
, and the rest of the population could be more likely from the end of April.
Corona: Moderna wants to apply for emergency approval for vaccine in the USA in the coming weeks
Update from November 16, 2:31 p.m.:
The
phase III study
for the
vaccine mRNA-1273 from
the US pharmaceutical company
Moderna
includes a total of
30,000 test subjects
.
Half of them received the
corona vaccine
, the other half act as a control group and receive a placebo.
So far, a total of 95 study participants have contracted
Covid-19
.
Of these, only 5 cases were actually vaccinated, 90 cases were diagnosed in the control group.
The
effectiveness of 94.5 percent is
calculated from this
.
This is about the extent to which the
vaccine
can prevent the disease.
So far there are no
data on the degree to which
mRNA-1273
prevents infection.
For
full vaccination protection
, two doses are necessary at intervals.
Moderna
plans to
apply for
emergency
approval from the US drug agency FDA
in the coming weeks
.
Applications to the
approval authorities in
other countries are also planned.
According to its own information, the company wants to be ready by the end of the year
to deliver
around
20 million vaccine doses
to the
USA
if it is
approved
.
Up to
a billion cans
are
expected to be
manufactured in the
coming year
.
Corona vaccine: EMA starts testing for Moderna vaccine
Update from November 16, 1:53 p.m.:
The
European Medicines Agency (EMA)
has started the
test procedure
for a
corona vaccine
from
Moderna Biotech
in Spain, a spin-off of the US company
Moderna
.
The CHMP scientific committee of the EMA had given the green light for the so-called
rolling review process
after the first promising results from studies
, the authority announced on Monday in
Amsterdam
.
Because the data is already evaluated as soon as they are available, and not only after a formal application has been made for marketing authorization, which can
process
up to the
approval
review process Rolling considerably with a
shortened
are.
With this
accelerated approval process
, pharmaceutical companies can
report
their
vaccine candidates
to
the EMA
in a kind of pre-approval process during the
clinical trial
phase
.
The data from ongoing studies are then submitted on an ongoing basis and assessed by the EMA.
In addition to
Moderna
,
Biontech / Pfizer
and the British-Swedish company
Astrazeneca
are currently
taking
this route.
How long the review will take is unclear.
As soon as there is sufficient evidence for the
effectiveness
as well as the
safety
and
quality of
the
vaccine
, approval for the
European market can be
applied for.
Corona vaccine: Moderna presents a vaccine with an effectiveness of 94.5 percent
Update from November 16, 1:17 p.m.:
With the US pharmaceutical company
Moderna
, another
manufacturer relevant
for
Europe has
submitted
relevant data for its
corona vaccine
.
The RNA vaccine has an
effectiveness of 94.5 percent
, it said in a statement from
Moderna
on Monday.
The EU Commission is negotiating with the US group about the delivery of up to
160 million vaccine doses
.
We just announced that mRNA-1273, our COVID-19 vaccine candidate, has met its primary efficacy endpoint in the first interim analysis of the Phase 3 COVE study.
Read more: https://t.co/vYWEy8CKCv pic.twitter.com/YuLubU1tlx
- Moderna (@moderna_tx) November 16, 2020
Corona vaccine: Biontech boss Sahin expects a return to normal at the end of 2021
First report from November 16:
Mainz - The number of infections with the
corona
virus
remains high
in
Germany
during the
second wave * of
the pandemic
.
A
partial lockdown
is already in place, on Monday Chancellor
Angela Merkel
and the Prime Minister will again discuss an adjustment of the
measures
.
Many people hope for a return to
normality
rests on the
corona vaccine
, which was developed by the Mainz-based pharmaceutical company
Biontech
and its US partner
Pfizer
.
The
Biontech CEO
and co-founder
Ugur Sahin *
does not
expect
a return to
normal
during the
Corona crisis
until winter 2021
.
In order to achieve this goal, a high
vaccination rate
against the
coronavirus * is
"absolutely essential" by autumn, said Sahin in an interview with the British television broadcaster
BBC
on Sunday
.
"I am confident that this will happen," he said.
Looking ahead to this year's cold season, the vaccine developer's board added: "This winter will be tough."
For the
time being, i.e. this winter, the
vaccine
will not have a major impact on the number of
infections
.
Sahin
announced that if everything continues to go well, the
vaccine will be delivered
from "late this year, early next year".
A medium-term goal of
Biontech
is to make more than
300 million cans available
worldwide
by April
.
"That could have an effect," said Sahin in relation to the
Corona situation *
.
Profile: Ugur Sahin and Ozlem Tureci
The Turkish-German husband-and-wife team responsible for the development of the world's first effective coronavirus vaccine.https: //t.co/kIPUNnu0Sz
- BBC Current Affairs (@BBC_CurrAff) November 15, 2020
Corona vaccine: Emergency approval should be applied for in November
The German company
Biontech *
and the US pharmaceutical
company Pfizer were the
first western manufacturers to present promising data from their
clinical tests
last Monday
.
Accordingly, your
vaccine
offers
more than
90 percent protection
against the
coronavirus *
.
According to reports, the companies want to
apply for
an
emergency
approval for the
corona vaccine
from the US Food and Drug Administration
this month
.
On Wednesday, the
EU Commission
formally
approved
a framework agreement with the companies
Biontech
and
Pfizer
for up to
300 million vaccine doses
.
Similar contracts are already in place with vaccine developers Johnson & Johnson, Astrazeneca and Sanofi-GSK for a total of up to 800 million doses of a
corona vaccine
.
Two other companies are in talks, said EU Health Commissioner
Stella Kyriakides
.
None of the manufacturers has yet been
approved for a
vaccine
against the
coronavirus *
.
(ph / dpa) * Merkur.de is part of the Ippen-Digital editorial network
List of rubric lists: © picture alliance / Friso Gentsch / dpa